Biojam España SL, resulting from the official presence of the Portuguese pharmaceutical company in this market, emerges as a significant milestone in its European expansion.
The signing of the deed consolidates the company's strategic entry into the Spanish scene, presenting itself as a decisive step towards partnership consolidation and the establishment of a solid presence. After dedicating special attention to Acute Lymphoblastic Leukemia, Biojam outlines its activity in the critical areas of General Surgery and Organ Transplantation. This new focus reflects the ongoing research for innovative solutions and advanced therapeutics, reinforcing the company's commitment to the development of cutting-edge medical approaches.
Anticipating a new phase of launches, Biojam announces that the new proposals and advances in the field of health will be available from January 2024. This announcement reinforces the company's commitment to contributing to the progress of medicine and the well-being of patients, promoting significant advancements in the European pharmaceutical landscape.
Biojam, Innovation is our DNA.
Madrid, November 2023
